What Is It? Why Is It Important? How To Detect It Early.
Decades of scientific research on Alzheimer’s, Parkinson’s, and other neurodegenerative diseases have led us to a paradigm shift in the way we look at these diseases: To us, these neurodegenerative diseases are all closely related and lie on the same spectrum.
We call it—the ParkinZheimer Spectrum.
In this article, we’ll shed light on why understanding ParkinZheimer is important in our work to finding the cure to end all neurodegenerative diseases, and why early detection holds the key in cracking the code in our mission for brain health.
“Alzheimer’s and Parkinson’s are diseases on a spectrum. We call it the ParkinZheimer Spectrum.”
Why Is ParkinZheimer Important?
Consider this: During the past three decades, Alzheimer’s and Parkinson’s drug development and clinical trials have failed to find a cure despite hefty spending of more than US$30 billion worldwide.
And yet, the need to find a cure for Alzheimer’s and Parkinson’s has never been greater. The number of people in the US diagnosed with Alzheimer’s and Parkinson’s is currently estimated at 5.8 million and, 1 million, respectively.
These numbers will increase nearly threefold by 2050 without effective treatments, according to The Alzheimer’s Association and Parkinson’s Foundation (Parkinson.org).
These organizations also project that the combined cost of caring for Alzheimer’s and Parkinson’s patients in the US will rise to approximately $1.3 trillion by 2050, threatening our economy.
This short video will give you more in-depth understanding of this global health challenge we face.
We believe the lack of successful drug development over the past three decades is due in large part to the way Alzheimer’s and Parkinson’s are perceived, namely that these are two distinct diseases, and therefore have been placed in separate silos.
To accelerate successful drug treatments, our scientists have gained significant new ground in an innovative technique to diagnose Alzheimer’s and Parkinson’s by tracking the biomarkers, aka Misfolded Protein or Prions, of both diseases. This has led us to the ParkinZheimer Spectrum thesis.
Watch this short video to learn more about Prions and the role they play in ParkinZheimer.
Thanks to advancements in molecular biology, for the first time in history, we are empowered to detect these biomarkers that drive the ParkinZheimer Spectrum. Early and with certainty. Why this change in paradigm?
“Because this new thinking gives us a new lens in looking at an old problem
where advancement had been impossible.”
At Amprion, our goal is to share our new approach in analyzing and diagnosing these elusive diseases to accelerate drug development in finding the cure before we lose another generation.
Science has advanced, and the time has come to expand our horizons in looking at these diseases as the ParkinZheimer Spectrum.
With this shift in paradigm, we now direct our focus on looking at these diseases through their similarities instead of their differences.
How To Detect Alzheimer’s and Parkinson’s With Certainty?
Amprion’s Prion Early Detection Science aims to gather newfound knowledge on how and when ParkinZheimer starts in the human body, leading the path to finding a cure. Interested in learning how Amprion’s early detection testing works?
Watch our Chief Scientific Officer, Claudio Soto, discusses the science behind Amprion’s early detection testing for ParkinZheimer.
When Can I Get Amprion’s Early Detection Testing?
Our FDA Breakthrough Device Designation for detecting Misfolded Protein Synuclein, biomarker related to Parkinson’s and a select group of Alzheimer’s patients, is expected to launch in selective markets in the first quarter of 2021.
If you’re interested in joining our Priority List for this test, please sign up.
To take Alzheimer’s or Parkinson’s Awareness quizzes, click on the links below. We respect your privacy and will only use these data for Amprion’s assessment for testing priorities.
At Amprion, we strive to crack the code on brain health and we believe Alzheimer’s and Parkinson’s and other neurodegenerative disease are all closely related. So close that they lie on the same spectrum: The ParkinZheimer Spectrum. Interested in learning more about ParkinZheimer?
Feedback? If you have any questions or comments on this article, please let us know. We’d love to hear from you.